LIF and acute myeloid leukemia: Moreover, as IL-6, OSM, and LIF utilize gp130 as a signaling component for high-affinity receptor complexes [28], targeting gp130 to inhibit autocrine LIF and OSM signaling could be another strategy for IDH-mutated AML therapy.